Also, the combination of PLG‐CA4 and PI3Kγ inhibitor markedly improved the tumor therapeutic effect of NLG919, an inhibitor of immune checkpoint indoleamine 2,3‐dioxygenase (IDO). This evidence concerns the gene IDO1 and neoplasm.